Status:
RECRUITING
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Conditions:
Pneumonia, Community-Acquired
COVID-19 Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction,...
Detailed Description
Post-acute pneumonia syndrome People believe that there is a "modern pandemic" beyond the pandemic. This is called the post-acute COVID syndrome (PACS), and it is a constellation of symptoms and medic...
Eligibility Criteria
Inclusion
- Group A (healthy controls)
- Adults (18 years or more) of both genders (Female/Male: 50/50 ratio)
- No history of severe pneumonia (sCAP, COVID-19 or HAP)
- Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD.
- Group B (CVRD controls)
- Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
- No history of severe pneumonia (sCAP, COVID-19 or HAP)
- At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD
- Group C (COVID-19 survivors)
- Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
- Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia
- SoC treatment for acute COVID-19 with dexamethasone
- Group D (sCAP survivors)
- Adults (18 years or more) of both genders
- Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit.
- SoC treatment for sCAP with antibiotics
Exclusion
- Group A (healthy controls)
- Presence of two or more comorbidities
- Any other co-existing disorder generating CVRD symptoms
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
- Group B (CVRD controls)
- Any other co-existing disorder generating CVRD symptoms
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
- Group C (COVID-19 survivors)
- Medical history of severe congestive heart failure (Stage III-IV)
- Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
- Group D (sCAP survivors)
- Medical history of severe congestive heart failure (Stage III-IV)
- Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
Key Trial Info
Start Date :
November 8 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 8 2028
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT06601998
Start Date
November 8 2024
End Date
June 8 2028
Last Update
November 17 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
2
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
3
1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS
Athens, Greece
4
1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.
Athens, Greece